Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (ALLR) following a series of events involving the company’s Dovitinib NDA and SEC investigations. Investors who suffered losses exceeding $50,000 between May 17, 2022 and July 19, 2024 are encouraged to contact Faruqi & Faruqi to discuss their legal options.